Category Archives: Generic drug

Médecins Sans Frontières Warns About IP Inclusion In Asian FTA

August 27,2014 The inclusion of intellectual property in the ongoing negotiations of the Regional Comprehensive Economic Partnership between 16 countries, most of them Asian, is raising concerns about “TRIPS-plus” measures that could jeopardise generic drugs production in India, according to … Continue reading

Posted in ASEAN, FTAs, Generic drug, IP Rights, patent, Right to Health, TRIPS plus | Tagged , , , , , , | Leave a comment

EU nations join forces against ‘exorbitant’ hepatitis C drug

Source: Yahoo News 30 July 2014 Paris (AFP) – France said Thursday it has joined forces with 13 other European countries to negotiate a lower price for a promising new hepatitis C drug that has drawn controversy for its astronomical … Continue reading

Posted in access to medicines, Drug Pricing, Generic drug, Hepatitis - C, patent, Sofosbuvir | Leave a comment

Getting cured of hepatitis C will cost you your pension

Source: Act Up Paris 28 July 2014 Sovaldi® (sofosbuvir), the new medicine against chronic hepatitis C from American laboratory Gilead, highly increases chances of recovery while also decreasing the side effects that make people stop the cure. A hope of … Continue reading

Posted in access to medicines, Compulsory Licensing, Drug Pricing, Generic drug, Hepatitis - C, IP Rights, patent | Leave a comment

Cost of Treatment against Hepatitis C: The French Government Must Issue a Compulsory License for Sofosbuvir and Seek the Usage of Generics

Source: Act Up Basel 28 July 2014 Act Up-Basel called the French government to learn from the current situation regarding access to new direct-acting antivirals (DAAs) molecules used in the treatment of hepatitis C (HCV), to exercise Article L613 -16 … Continue reading

Posted in access to medicines, Compulsory Licensing, Drug Pricing, Generic drug, Hepatitis - C, patent | Leave a comment

Hepatitis C drugs not reaching poor

Source: Nature 14 July 2014 Treatment guidelines for virus highlight challenge of paying for expensive drugs in low-income countries. The publication last week of the first treatment guidelines for hepatitis C virus (HCV), and the advent of drugs that can … Continue reading

Posted in Drug Pricing, Generic drug, IP Rights, patent | Leave a comment

More MSF patients with DR-TB gain access to dramatically cheaper version of life-saving drug

Patients & MSF doctors elated as MCC approval for MSF to use generic linezolid paves the way for national registration and access 02 July 2014 After a three-year long struggle, Médecins Sans Frontières (MSF) has received approval from the South African … Continue reading

Posted in Drug Pricing, Generic drug, Intellectual Property, patent | Leave a comment

Natco seeks to block Gilead’s hepatitis C drug patent in India: source

Source: Reuters 11 April 2014 (Reuters) – India’s Natco Pharma Ltd has formally asked the Indian patent office to deny U.S. drugmaker Gilead Sciences Inc’s new hepatitis C drug Sovaldi a patent in India, a source with direct knowledge of the matter said. … Continue reading

Posted in Generic drug, Hepatitis - C, patent, Patent Opposition | Tagged , , | Leave a comment